Successfully obtained antibodies with neutralizing activity against the novel coronavirus.

Kyoto Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Tokyo) has revealed that the human-type neutralizing antibody clone ABW2000, jointly developed with Abwiz Bio Inc. (Headquarters: San Diego, California, USA) in collaboration with Yokohama City University (Kanagawa Prefecture, Yokohama), demonstrates strong neutralizing activity (IC50 less than 60 ng/mL) not only against the wild-type strain (Wuhan strain) but also against the UK strain with N501Y and D614G mutations, as well as the South African and Brazilian strains with the E484K mutation.

Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration
Related Links
Successfully obtained antibodies with neutralizing activity against the novel coronavirus